Back

Effects of semaglutide on walking distance, symptoms and rescue treatment by baseline medical therapy and LDL cholesterol levels: insights from the STRIDE trial

31 August 2026 (09:05 - 09:15)
Organised by: Logo
Congress Presentation Part of: Modulation of risk and outcomes in peripheral artery disease Intervention ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Marc Bonaca

University of Colorado Anschutz Medical Campus, Aurora (United States of America)

5 More presentations in this session

Presentation thumbnail
Multistate modeling of clinical trajectories and transition-specific risk patterns in peripheral artery disease
Doctor Y. ZHANG (Shatin, HK) Doctor G. Tan (Shatin, HK)
Abstract Slides
Presentation thumbnail
Subcutaneous semaglutide and peripheral arterial occlusive disease in type 2 diabetes: network meta-analysis of randomized trials
Doctor M. Movahed (Tucson, US)
Abstract Slides
Presentation thumbnail
Adherence to statins with risk of cardiovascular and limb events in peripheral artery disease
Doctor M. Ude (Dallas, US)
Abstract Slides
Presentation thumbnail
Prevalence of high inflammatory risk (hsCRP ≥2 mg/L) in European patients with atherosclerotic cardiovascular disease with/without chronic kidney disease: sub-analysis of the global POSEIDON study
Professor D. Leistner (Frankfurt, DE)
Abstract Slides
Presentation thumbnail
A novel machine learning derived proteomics-leveraged panel to predict presence and prognosis of obstructive peripheral artery disease: the CASABLANCA Study
Professor J. Januzzi (Boston, US)
Abstract Slides

Access the full session

Session thumbnail
Modulation of risk and outcomes in peripheral artery disease

The Event

Event poster

ESC Congress 2026

31 August 2026 09:05 CET
You may be interested in
thumbnail
Congress Presentation
Effects of semaglutide on functional capacity in patients with type 2 diabetes and peripheral arterial disease: rationale and design of the STRIDE trial
27 August 2021
thumbnail
Congress Presentation
Prognostic impact of achieving LDL cholesterol guidelines-recommended target in secondary prevention: a real-world study
27 August 2021
thumbnail
Congress Presentation
What determines the 6-minute walk distance in patients with transthyretin cardiomyopathy?
22 May 2023
thumbnail
Congress Presentation
Relationship between baseline LDL cholesterol levels and cardiovascular outcomes in adults with cardiovascular disease and overweight or obesity: an exploratory analysis of the SELECT trial
1 September 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources